Kevin Herde - 25 Jan 2022 Form 4 Insider Report for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

Role: Chief Financial Officer
Signature: /s/ Kurt Oreshack, by power of attorney for Kevin Herde
Issuer symbol: MRVI
Transactions as of: 25 Jan 2022
Net transactions value: +$20,403
Form type: 4
Filing time: 27 Jan 2022, 15:00:30 UTC
Next filing: 27 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRVI	Class A Common Stock	Award	$11,406	+497		$22.95	497	30 Apr 2021	Direct	F1
transaction	MRVI	Class A Common Stock	Award	$8,996	+392	+79%	$22.95	889	31 Oct 2021	Direct	F1
transaction	MRVI	Class A Common Stock	Award		+19,500	+2193%		20,389	25 Jan 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRVI	Employee Stock Option (Right to Buy)	Award	$0	+36,200		$0.000000	36,200	25 Jan 2022	Class A Common Stock	36,200	$26.32	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 889 shares of Class A Common Stock was also exempt pursuant to Rule 16b-3(c).
F2	Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the reporting person's continued employment with the Issuer.
F3	Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer.